ERBB2 and melanoma: However, the success of most targeted therapies is predicated upon the patient's tumor exhibiting a specific targetable genomic lesion, for example V600E B-Raf in melanoma, or ERBB2 (HER2) gene amplification in breast cancer, both of which lead to increased downstream signaling and tumorigenic activity.